Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis

(2019) Amanda Mogul et al.   ANNALS OF PHARMACOTHERAPY

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

(2019) Wenhui Xie et al.   ANNALS OF THE RHEUMATIC DISEASES

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients

(2018) Rishi J. Desai et al.   Arthritis & Rheumatology

VigiBase, the WHO Global ICSR Database System: Basic Facts

(2017) Marie Lindquist   DRUG INFORMATION JOURNAL

Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis

(2014) Patompong Ungprasert et al.   CLINICAL RHEUMATOLOGY

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia

(2013) Izyan A.Wahab et al.   DRUG SAFETY

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY